{"id":3697,"date":"2026-09-13T18:02:24","date_gmt":"2026-09-13T18:02:24","guid":{"rendered":"https:\/\/indiamedicine.org\/?p=3697"},"modified":"2026-09-13T18:04:00","modified_gmt":"2026-09-13T18:04:00","slug":"understanding-schedule-m-2026-gmp-compliance-india","status":"publish","type":"post","link":"https:\/\/indiamedicine.org\/?p=3697","title":{"rendered":"Schedule M 2026 Explained: GMP Compliance Rules for Indian Pharma"},"content":{"rendered":"\n\n<h2 class=\"wp-block-heading\">&#x26a0;&#xfe0f; Challenges in the Transition Period<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The transition to the revised Schedule M has not been smooth for all manufacturers. Several challenges have been reported in the industry press:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Small and medium manufacturers struggling:<\/strong> The Economic Times reported in January 2026 that <strong>only 11% of pharmaceutical units in Himachal Pradesh<\/strong> were fully GMP-compliant under the revised Schedule M, highlighting the scale of the compliance gap among smaller manufacturers.<\/li>\n<li><strong>Extension debates:<\/strong> The government has been discussing whether to grant a one-year extension for small and medium pharma firms to meet the new compliance deadlines, as reported by <strong>KNN India<\/strong> and <strong>Business Standard<\/strong> in December 2025. As of September 2026, the final extension policy was still being finalized \u2014 buyers should check the latest CDSCO guidance.<\/li>\n<li><strong>State-level enforcement:<\/strong> The Telangana Drug Control Administration issued stop-production orders to several companies for non-compliance with the revised Schedule M in early 2026, per <strong>Pharmabiz<\/strong>. This signals that enforcement is becoming more active.<\/li>\n<li><strong>Cough syrup manufacturer audits:<\/strong> In August 2026, over <strong>1,000 cough syrup manufacturers<\/strong> were subjected to intensified audits following quality concerns, as reported by <strong>The New Indian Express<\/strong> \u2014 a clear sign that the regulator is prioritizing high-volume, high-risk product categories.<\/li>\n<\/ul>\n\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f50d; Practical Checklist: Verifying Schedule M Compliance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">If you are buying Indian generic medicines \u2014 whether as a pharmacy, hospital procurement officer, or individual consumer \u2014 use this checklist to verify that the manufacturer takes GMP compliance seriously:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>&#x2705; Request the GMP certificate:<\/strong> Ask the manufacturer or supplier for a copy of their current GMP certificate issued by the state drug control authority. Verify the certificate number with the issuing authority if possible.<\/li>\n<li><strong>&#x2705; Check the CDSCO portal:<\/strong> The CDSCO website (<a href=\"https:\/\/www.cdsco.gov.in\" target=\"_blank\" rel=\"noopener\">cdsco.gov.in<\/a>) provides regulatory information including manufacturer registrations and approval statuses. Cross-check the manufacturer name.<\/li>\n<li><strong>&#x2705; Look for WHO-GMP certification:<\/strong> Manufacturers that have achieved WHO-GMP certification are listed on the WHO Prequalification website. This is a higher benchmark and a strong positive signal.<\/li>\n<li><strong>&#x2705; Verify batch numbers and expiry dates:<\/strong> Every legitimate product should have a clearly printed batch number and expiry date on the packaging \u2014 this is a Schedule M requirement.<\/li>\n<li><strong>&#x26a0;&#xfe0f; Watch for red flags:<\/strong> Missing or unclear labeling, lack of manufacturer address, unusually low prices, and products without batch numbers are all warning signs that the manufacturer may not be compliant.<\/li>\n<li><strong>&#x2705; Use verified distributors:<\/strong> For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>. Working with verified distributors reduces the risk of sourcing non-compliant products.<\/li>\n<\/ul>\n\n\n\n\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Compliance Trajectory<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The revised Schedule M is part of a broader pattern of regulatory tightening and modernization by the CDSCO throughout 2025 and 2026. Key developments include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Outsourced GMP audits:<\/strong> The CDSCO&#8217;s plan to outsource GMP inspections to accredited agencies (announced February 2026) is intended to increase inspection capacity and credibility.<\/li>\n<li><strong>1,500-person scientific cadre:<\/strong> Building a larger pool of trained regulatory experts to support inspection and oversight functions, addressing a long-standing capacity constraint.<\/li>\n<li><strong>Digital regulatory platform:<\/strong> The DCGI has announced that the CDSCO will launch the first phase of an end-to-end digital drug regulatory platform within 18 months (as of August 2026), which is expected to streamline approval and compliance tracking workflows.<\/li>\n<li><strong>Risk-based regulation:<\/strong> The September 2026 announcement of a risk-based regulatory framework complements Schedule M by calibrating the intensity of oversight to the risk profile of the manufacturer and product.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Together, these initiatives signal a regulator that is moving toward greater transparency, capacity, and consistency \u2014 a net positive for buyers who depend on the reliability of Indian-manufactured generic medicines.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Sources: The Economic Times (January 2026) \u2014 &#8220;Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant&#8221;; Pharmabiz (February 2026) \u2014 &#8220;CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre&#8221;; The New Indian Express (August 2026) \u2014 &#8220;Over 1000 cough syrup manufacturers undergo intense audits&#8221;; IndiaMedToday (February 2026) \u2014 CDSCO regulatory overhaul reporting; KNN India and Business Standard (December 2025) \u2014 Schedule M extension discussions. Details sourced via Google News RSS as of September 14, 2026.\n<p class=\"wp-block-paragraph\">For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4ca; Why Schedule M Matters for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For hospitals, pharmacies, and individual buyers of Indian generic medicines, Schedule M compliance is a <strong>quality signal<\/strong>. A manufacturer that complies with the revised Schedule M has demonstrated that its production processes meet defined quality standards. Here is what buyers should understand:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Compliance equals traceability:<\/strong> Schedule M requires manufacturers to maintain batch records that allow full traceability of every product from raw materials to finished goods. If a quality issue arises, compliant manufacturers can identify and recall affected batches.<\/li>\n<li><strong>GMP certification is verifiable:<\/strong> Buyers should check that the manufacturer holds a valid GMP certificate issued by the state drug control authority or the CDSCO. The absence of this certificate is a red flag.<\/li>\n<li><strong>Schedule M is not the same as WHO prequalification:<\/strong> While Schedule M alignment with WHO-GMP is a positive step, WHO prequalification is a separate, more rigorous process required for procurement by UN agencies and some international tenders. Buyers sourcing for regulated markets should verify both.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x26a0;&#xfe0f; Challenges in the Transition Period<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The transition to the revised Schedule M has not been smooth for all manufacturers. Several challenges have been reported in the industry press:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Small and medium manufacturers struggling:<\/strong> The Economic Times reported in January 2026 that <strong>only 11% of pharmaceutical units in Himachal Pradesh<\/strong> were fully GMP-compliant under the revised Schedule M, highlighting the scale of the compliance gap among smaller manufacturers.<\/li>\n<li><strong>Extension debates:<\/strong> The government has been discussing whether to grant a one-year extension for small and medium pharma firms to meet the new compliance deadlines, as reported by <strong>KNN India<\/strong> and <strong>Business Standard<\/strong> in December 2025. As of September 2026, the final extension policy was still being finalized \u2014 buyers should check the latest CDSCO guidance.<\/li>\n<li><strong>State-level enforcement:<\/strong> The Telangana Drug Control Administration issued stop-production orders to several companies for non-compliance with the revised Schedule M in early 2026, per <strong>Pharmabiz<\/strong>. This signals that enforcement is becoming more active.<\/li>\n<li><strong>Cough syrup manufacturer audits:<\/strong> In August 2026, over <strong>1,000 cough syrup manufacturers<\/strong> were subjected to intensified audits following quality concerns, as reported by <strong>The New Indian Express<\/strong> \u2014 a clear sign that the regulator is prioritizing high-volume, high-risk product categories.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f50d; Practical Checklist: Verifying Schedule M Compliance<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>If you are buying Indian generic medicines \u2014 whether as a pharmacy, hospital procurement officer, or individual consumer \u2014 use this checklist to verify that the manufacturer takes GMP compliance seriously:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>&#x2705; Request the GMP certificate:<\/strong> Ask the manufacturer or supplier for a copy of their current GMP certificate issued by the state drug control authority. Verify the certificate number with the issuing authority if possible.<\/li>\n<li><strong>&#x2705; Check the CDSCO portal:<\/strong> The CDSCO website (<a href=\"https:\/\/www.cdsco.gov.in\" target=\"_blank\" rel=\"noopener\">cdsco.gov.in<\/a>) provides regulatory information including manufacturer registrations and approval statuses. Cross-check the manufacturer name.<\/li>\n<li><strong>&#x2705; Look for WHO-GMP certification:<\/strong> Manufacturers that have achieved WHO-GMP certification are listed on the WHO Prequalification website. This is a higher benchmark and a strong positive signal.<\/li>\n<li><strong>&#x2705; Verify batch numbers and expiry dates:<\/strong> Every legitimate product should have a clearly printed batch number and expiry date on the packaging \u2014 this is a Schedule M requirement.<\/li>\n<li><strong>&#x26a0;&#xfe0f; Watch for red flags:<\/strong> Missing or unclear labeling, lack of manufacturer address, unusually low prices, and products without batch numbers are all warning signs that the manufacturer may not be compliant.<\/li>\n<li><strong>&#x2705; Use verified distributors:<\/strong> For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>. Working with verified distributors reduces the risk of sourcing non-compliant products.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Compliance Trajectory<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The revised Schedule M is part of a broader pattern of regulatory tightening and modernization by the CDSCO throughout 2025 and 2026. Key developments include:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Outsourced GMP audits:<\/strong> The CDSCO&#8217;s plan to outsource GMP inspections to accredited agencies (announced February 2026) is intended to increase inspection capacity and credibility.<\/li>\n<li><strong>1,500-person scientific cadre:<\/strong> Building a larger pool of trained regulatory experts to support inspection and oversight functions, addressing a long-standing capacity constraint.<\/li>\n<li><strong>Digital regulatory platform:<\/strong> The DCGI has announced that the CDSCO will launch the first phase of an end-to-end digital drug regulatory platform within 18 months (as of August 2026), which is expected to streamline approval and compliance tracking workflows.<\/li>\n<li><strong>Risk-based regulation:<\/strong> The September 2026 announcement of a risk-based regulatory framework complements Schedule M by calibrating the intensity of oversight to the risk profile of the manufacturer and product.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>Together, these initiatives signal a regulator that is moving toward greater transparency, capacity, and consistency \u2014 a net positive for buyers who depend on the reliability of Indian-manufactured generic medicines.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: The Economic Times (January 2026) \u2014 &#8220;Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant&#8221;; Pharmabiz (February 2026) \u2014 &#8220;CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre&#8221;; The New Indian Express (August 2026) \u2014 &#8220;Over 1000 cough syrup manufacturers undergo intense audits&#8221;; IndiaMedToday (February 2026) \u2014 CDSCO regulatory overhaul reporting; KNN India and Business Standard (December 2025) \u2014 Schedule M extension discussions. Details sourced via Google News RSS as of September 14, 2026.<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:post-content --><!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4c9; The 2026 Revised Schedule M: Key Changes<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The revised Schedule M, which has been rolling out through 2025 and 2026, marks a significant upgrade from the earlier version. According to reporting by <strong>The Economic Times<\/strong> and <strong>Pharmabiz<\/strong>, the updated compliance framework introduces several important changes:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>WHO-GMP alignment:<\/strong> The revised rules bring Indian GMP standards closer to WHO-GMP benchmarks, making Indian-manufactured drugs more acceptable in regulated international markets such as the US, EU, and UK.<\/li>\n<li><strong>Risk-based approach:<\/strong> Pharmaceutical manufacturers are now expected to implement a risk-based quality management system \u2014 higher-risk products and processes receive more intensive controls, drawing from the same principles as the CDSCO&#8217;s broader risk-based regulation drive announced in September 2026.<\/li>\n<li><strong>Expanded scope for data integrity:<\/strong> Documentation and data integrity requirements have been strengthened \u2014 batch records, laboratory data, and qualitycontrol documents must be complete, attributable, and tamper-proof.<\/li>\n<li><strong>Stronger facility and equipment requirements:<\/strong> Cleanroom classifications, HVAC systems, water-for-injection (WFI) systems, and equipment calibration and validation standards have been tightened.<\/li>\n<li><strong>Structured audits and inspections:<\/strong> The CDSCO has announced plans to <strong>outsource GMP audits<\/strong> to accredited third-party agencies and to build a <strong>1,500-person scientific cadre<\/strong> to support regulatory oversight, as reported by IndiaMedToday in February 2026.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4ca; Why Schedule M Matters for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For hospitals, pharmacies, and individual buyers of Indian generic medicines, Schedule M compliance is a <strong>quality signal<\/strong>. A manufacturer that complies with the revised Schedule M has demonstrated that its production processes meet defined quality standards. Here is what buyers should understand:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Compliance equals traceability:<\/strong> Schedule M requires manufacturers to maintain batch records that allow full traceability of every product from raw materials to finished goods. If a quality issue arises, compliant manufacturers can identify and recall affected batches.<\/li>\n<li><strong>GMP certification is verifiable:<\/strong> Buyers should check that the manufacturer holds a valid GMP certificate issued by the state drug control authority or the CDSCO. The absence of this certificate is a red flag.<\/li>\n<li><strong>Schedule M is not the same as WHO prequalification:<\/strong> While Schedule M alignment with WHO-GMP is a positive step, WHO prequalification is a separate, more rigorous process required for procurement by UN agencies and some international tenders. Buyers sourcing for regulated markets should verify both.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x26a0;&#xfe0f; Challenges in the Transition Period<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The transition to the revised Schedule M has not been smooth for all manufacturers. Several challenges have been reported in the industry press:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Small and medium manufacturers struggling:<\/strong> The Economic Times reported in January 2026 that <strong>only 11% of pharmaceutical units in Himachal Pradesh<\/strong> were fully GMP-compliant under the revised Schedule M, highlighting the scale of the compliance gap among smaller manufacturers.<\/li>\n<li><strong>Extension debates:<\/strong> The government has been discussing whether to grant a one-year extension for small and medium pharma firms to meet the new compliance deadlines, as reported by <strong>KNN India<\/strong> and <strong>Business Standard<\/strong> in December 2025. As of September 2026, the final extension policy was still being finalized \u2014 buyers should check the latest CDSCO guidance.<\/li>\n<li><strong>State-level enforcement:<\/strong> The Telangana Drug Control Administration issued stop-production orders to several companies for non-compliance with the revised Schedule M in early 2026, per <strong>Pharmabiz<\/strong>. This signals that enforcement is becoming more active.<\/li>\n<li><strong>Cough syrup manufacturer audits:<\/strong> In August 2026, over <strong>1,000 cough syrup manufacturers<\/strong> were subjected to intensified audits following quality concerns, as reported by <strong>The New Indian Express<\/strong> \u2014 a clear sign that the regulator is prioritizing high-volume, high-risk product categories.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f50d; Practical Checklist: Verifying Schedule M Compliance<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>If you are buying Indian generic medicines \u2014 whether as a pharmacy, hospital procurement officer, or individual consumer \u2014 use this checklist to verify that the manufacturer takes GMP compliance seriously:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>&#x2705; Request the GMP certificate:<\/strong> Ask the manufacturer or supplier for a copy of their current GMP certificate issued by the state drug control authority. Verify the certificate number with the issuing authority if possible.<\/li>\n<li><strong>&#x2705; Check the CDSCO portal:<\/strong> The CDSCO website (<a href=\"https:\/\/www.cdsco.gov.in\" target=\"_blank\" rel=\"noopener\">cdsco.gov.in<\/a>) provides regulatory information including manufacturer registrations and approval statuses. Cross-check the manufacturer name.<\/li>\n<li><strong>&#x2705; Look for WHO-GMP certification:<\/strong> Manufacturers that have achieved WHO-GMP certification are listed on the WHO Prequalification website. This is a higher benchmark and a strong positive signal.<\/li>\n<li><strong>&#x2705; Verify batch numbers and expiry dates:<\/strong> Every legitimate product should have a clearly printed batch number and expiry date on the packaging \u2014 this is a Schedule M requirement.<\/li>\n<li><strong>&#x26a0;&#xfe0f; Watch for red flags:<\/strong> Missing or unclear labeling, lack of manufacturer address, unusually low prices, and products without batch numbers are all warning signs that the manufacturer may not be compliant.<\/li>\n<li><strong>&#x2705; Use verified distributors:<\/strong> For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>. Working with verified distributors reduces the risk of sourcing non-compliant products.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Compliance Trajectory<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The revised Schedule M is part of a broader pattern of regulatory tightening and modernization by the CDSCO throughout 2025 and 2026. Key developments include:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Outsourced GMP audits:<\/strong> The CDSCO&#8217;s plan to outsource GMP inspections to accredited agencies (announced February 2026) is intended to increase inspection capacity and credibility.<\/li>\n<li><strong>1,500-person scientific cadre:<\/strong> Building a larger pool of trained regulatory experts to support inspection and oversight functions, addressing a long-standing capacity constraint.<\/li>\n<li><strong>Digital regulatory platform:<\/strong> The DCGI has announced that the CDSCO will launch the first phase of an end-to-end digital drug regulatory platform within 18 months (as of August 2026), which is expected to streamline approval and compliance tracking workflows.<\/li>\n<li><strong>Risk-based regulation:<\/strong> The September 2026 announcement of a risk-based regulatory framework complements Schedule M by calibrating the intensity of oversight to the risk profile of the manufacturer and product.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>Together, these initiatives signal a regulator that is moving toward greater transparency, capacity, and consistency \u2014 a net positive for buyers who depend on the reliability of Indian-manufactured generic medicines.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: The Economic Times (January 2026) \u2014 &#8220;Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant&#8221;; Pharmabiz (February 2026) \u2014 &#8220;CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre&#8221;; The New Indian Express (August 2026) \u2014 &#8220;Over 1000 cough syrup manufacturers undergo intense audits&#8221;; IndiaMedToday (February 2026) \u2014 CDSCO regulatory overhaul reporting; KNN India and Business Standard (December 2025) \u2014 Schedule M extension discussions. Details sourced via Google News RSS as of September 14, 2026.<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:post-content --><!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f3ec; What Is Schedule M?<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Schedule M is the section of India&#8217;s <strong>Drugs and Cosmetics Rules, 1945<\/strong> that lays down the <strong>Good Manufacturing Practices (GMP)<\/strong> requirements for pharmaceutical manufacturers. Originally introduced as a set of basic hygiene and documentation standards, Schedule M has been progressively upgraded to align with international GMP benchmarks, including the World Health Organization&#8217;s WHO-GMP guidelines and the European Union&#8217;s EudraGMP standards.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Any manufacturing facility that produces pharmaceutical products for sale in India must comply with Schedule M. The rules cover every aspect of production:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>Premises and plant design \u2014 clean areas, air handling, water systems<\/li>\n<li>Raw material sourcing, testing, and storage<\/li>\n<li>Manufacturing process controls and batch records<\/li>\n<li>Quality control laboratory operations<\/li>\n<li>Packaging, labeling, and dispatch procedures<\/li>\n<li>Personnel training, qualification, and hygiene<\/li>\n<li>Documentation, record-keeping, and traceability<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4c9; The 2026 Revised Schedule M: Key Changes<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The revised Schedule M, which has been rolling out through 2025 and 2026, marks a significant upgrade from the earlier version. According to reporting by <strong>The Economic Times<\/strong> and <strong>Pharmabiz<\/strong>, the updated compliance framework introduces several important changes:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>WHO-GMP alignment:<\/strong> The revised rules bring Indian GMP standards closer to WHO-GMP benchmarks, making Indian-manufactured drugs more acceptable in regulated international markets such as the US, EU, and UK.<\/li>\n<li><strong>Risk-based approach:<\/strong> Pharmaceutical manufacturers are now expected to implement a risk-based quality management system \u2014 higher-risk products and processes receive more intensive controls, drawing from the same principles as the CDSCO&#8217;s broader risk-based regulation drive announced in September 2026.<\/li>\n<li><strong>Expanded scope for data integrity:<\/strong> Documentation and data integrity requirements have been strengthened \u2014 batch records, laboratory data, and qualitycontrol documents must be complete, attributable, and tamper-proof.<\/li>\n<li><strong>Stronger facility and equipment requirements:<\/strong> Cleanroom classifications, HVAC systems, water-for-injection (WFI) systems, and equipment calibration and validation standards have been tightened.<\/li>\n<li><strong>Structured audits and inspections:<\/strong> The CDSCO has announced plans to <strong>outsource GMP audits<\/strong> to accredited third-party agencies and to build a <strong>1,500-person scientific cadre<\/strong> to support regulatory oversight, as reported by IndiaMedToday in February 2026.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4ca; Why Schedule M Matters for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For hospitals, pharmacies, and individual buyers of Indian generic medicines, Schedule M compliance is a <strong>quality signal<\/strong>. A manufacturer that complies with the revised Schedule M has demonstrated that its production processes meet defined quality standards. Here is what buyers should understand:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Compliance equals traceability:<\/strong> Schedule M requires manufacturers to maintain batch records that allow full traceability of every product from raw materials to finished goods. If a quality issue arises, compliant manufacturers can identify and recall affected batches.<\/li>\n<li><strong>GMP certification is verifiable:<\/strong> Buyers should check that the manufacturer holds a valid GMP certificate issued by the state drug control authority or the CDSCO. The absence of this certificate is a red flag.<\/li>\n<li><strong>Schedule M is not the same as WHO prequalification:<\/strong> While Schedule M alignment with WHO-GMP is a positive step, WHO prequalification is a separate, more rigorous process required for procurement by UN agencies and some international tenders. Buyers sourcing for regulated markets should verify both.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x26a0;&#xfe0f; Challenges in the Transition Period<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The transition to the revised Schedule M has not been smooth for all manufacturers. Several challenges have been reported in the industry press:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Small and medium manufacturers struggling:<\/strong> The Economic Times reported in January 2026 that <strong>only 11% of pharmaceutical units in Himachal Pradesh<\/strong> were fully GMP-compliant under the revised Schedule M, highlighting the scale of the compliance gap among smaller manufacturers.<\/li>\n<li><strong>Extension debates:<\/strong> The government has been discussing whether to grant a one-year extension for small and medium pharma firms to meet the new compliance deadlines, as reported by <strong>KNN India<\/strong> and <strong>Business Standard<\/strong> in December 2025. As of September 2026, the final extension policy was still being finalized \u2014 buyers should check the latest CDSCO guidance.<\/li>\n<li><strong>State-level enforcement:<\/strong> The Telangana Drug Control Administration issued stop-production orders to several companies for non-compliance with the revised Schedule M in early 2026, per <strong>Pharmabiz<\/strong>. This signals that enforcement is becoming more active.<\/li>\n<li><strong>Cough syrup manufacturer audits:<\/strong> In August 2026, over <strong>1,000 cough syrup manufacturers<\/strong> were subjected to intensified audits following quality concerns, as reported by <strong>The New Indian Express<\/strong> \u2014 a clear sign that the regulator is prioritizing high-volume, high-risk product categories.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f50d; Practical Checklist: Verifying Schedule M Compliance<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>If you are buying Indian generic medicines \u2014 whether as a pharmacy, hospital procurement officer, or individual consumer \u2014 use this checklist to verify that the manufacturer takes GMP compliance seriously:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>&#x2705; Request the GMP certificate:<\/strong> Ask the manufacturer or supplier for a copy of their current GMP certificate issued by the state drug control authority. Verify the certificate number with the issuing authority if possible.<\/li>\n<li><strong>&#x2705; Check the CDSCO portal:<\/strong> The CDSCO website (<a href=\"https:\/\/www.cdsco.gov.in\" target=\"_blank\" rel=\"noopener\">cdsco.gov.in<\/a>) provides regulatory information including manufacturer registrations and approval statuses. Cross-check the manufacturer name.<\/li>\n<li><strong>&#x2705; Look for WHO-GMP certification:<\/strong> Manufacturers that have achieved WHO-GMP certification are listed on the WHO Prequalification website. This is a higher benchmark and a strong positive signal.<\/li>\n<li><strong>&#x2705; Verify batch numbers and expiry dates:<\/strong> Every legitimate product should have a clearly printed batch number and expiry date on the packaging \u2014 this is a Schedule M requirement.<\/li>\n<li><strong>&#x26a0;&#xfe0f; Watch for red flags:<\/strong> Missing or unclear labeling, lack of manufacturer address, unusually low prices, and products without batch numbers are all warning signs that the manufacturer may not be compliant.<\/li>\n<li><strong>&#x2705; Use verified distributors:<\/strong> For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>. Working with verified distributors reduces the risk of sourcing non-compliant products.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Compliance Trajectory<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The revised Schedule M is part of a broader pattern of regulatory tightening and modernization by the CDSCO throughout 2025 and 2026. Key developments include:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Outsourced GMP audits:<\/strong> The CDSCO&#8217;s plan to outsource GMP inspections to accredited agencies (announced February 2026) is intended to increase inspection capacity and credibility.<\/li>\n<li><strong>1,500-person scientific cadre:<\/strong> Building a larger pool of trained regulatory experts to support inspection and oversight functions, addressing a long-standing capacity constraint.<\/li>\n<li><strong>Digital regulatory platform:<\/strong> The DCGI has announced that the CDSCO will launch the first phase of an end-to-end digital drug regulatory platform within 18 months (as of August 2026), which is expected to streamline approval and compliance tracking workflows.<\/li>\n<li><strong>Risk-based regulation:<\/strong> The September 2026 announcement of a risk-based regulatory framework complements Schedule M by calibrating the intensity of oversight to the risk profile of the manufacturer and product.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>Together, these initiatives signal a regulator that is moving toward greater transparency, capacity, and consistency \u2014 a net positive for buyers who depend on the reliability of Indian-manufactured generic medicines.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: The Economic Times (January 2026) \u2014 &#8220;Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant&#8221;; Pharmabiz (February 2026) \u2014 &#8220;CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre&#8221;; The New Indian Express (August 2026) \u2014 &#8220;Over 1000 cough syrup manufacturers undergo intense audits&#8221;; IndiaMedToday (February 2026) \u2014 CDSCO regulatory overhaul reporting; KNN India and Business Standard (December 2025) \u2014 Schedule M extension discussions. Details sourced via Google News RSS as of September 14, 2026.<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:post-content --><!-- \/wp:heading --><!-- wp:post-content --><!-- wp:paragraph -->\n<p>The Central Drugs Standard Control Organisation (CDSCO) has been steadily tightening India&#8217;s drug manufacturing quality standards through the revised <strong>Schedule M<\/strong> of the Drugs and Cosmetics Rules. For pharmaceutical manufacturers, distributors, and buyers of Indian generic medicines, understanding these compliance requirements is no longer optional \u2014 it is essential for ensuring drug safety, market access, and regulatory standing. This guide explains what Schedule M is, how the 2026 updates change the compliance landscape, and what each stakeholder needs to know.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f3ec; What Is Schedule M?<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Schedule M is the section of India&#8217;s <strong>Drugs and Cosmetics Rules, 1945<\/strong> that lays down the <strong>Good Manufacturing Practices (GMP)<\/strong> requirements for pharmaceutical manufacturers. Originally introduced as a set of basic hygiene and documentation standards, Schedule M has been progressively upgraded to align with international GMP benchmarks, including the World Health Organization&#8217;s WHO-GMP guidelines and the European Union&#8217;s EudraGMP standards.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>Any manufacturing facility that produces pharmaceutical products for sale in India must comply with Schedule M. The rules cover every aspect of production:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>Premises and plant design \u2014 clean areas, air handling, water systems<\/li>\n<li>Raw material sourcing, testing, and storage<\/li>\n<li>Manufacturing process controls and batch records<\/li>\n<li>Quality control laboratory operations<\/li>\n<li>Packaging, labeling, and dispatch procedures<\/li>\n<li>Personnel training, qualification, and hygiene<\/li>\n<li>Documentation, record-keeping, and traceability<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4c9; The 2026 Revised Schedule M: Key Changes<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The revised Schedule M, which has been rolling out through 2025 and 2026, marks a significant upgrade from the earlier version. According to reporting by <strong>The Economic Times<\/strong> and <strong>Pharmabiz<\/strong>, the updated compliance framework introduces several important changes:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>WHO-GMP alignment:<\/strong> The revised rules bring Indian GMP standards closer to WHO-GMP benchmarks, making Indian-manufactured drugs more acceptable in regulated international markets such as the US, EU, and UK.<\/li>\n<li><strong>Risk-based approach:<\/strong> Pharmaceutical manufacturers are now expected to implement a risk-based quality management system \u2014 higher-risk products and processes receive more intensive controls, drawing from the same principles as the CDSCO&#8217;s broader risk-based regulation drive announced in September 2026.<\/li>\n<li><strong>Expanded scope for data integrity:<\/strong> Documentation and data integrity requirements have been strengthened \u2014 batch records, laboratory data, and qualitycontrol documents must be complete, attributable, and tamper-proof.<\/li>\n<li><strong>Stronger facility and equipment requirements:<\/strong> Cleanroom classifications, HVAC systems, water-for-injection (WFI) systems, and equipment calibration and validation standards have been tightened.<\/li>\n<li><strong>Structured audits and inspections:<\/strong> The CDSCO has announced plans to <strong>outsource GMP audits<\/strong> to accredited third-party agencies and to build a <strong>1,500-person scientific cadre<\/strong> to support regulatory oversight, as reported by IndiaMedToday in February 2026.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f4ca; Why Schedule M Matters for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For hospitals, pharmacies, and individual buyers of Indian generic medicines, Schedule M compliance is a <strong>quality signal<\/strong>. A manufacturer that complies with the revised Schedule M has demonstrated that its production processes meet defined quality standards. Here is what buyers should understand:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Compliance equals traceability:<\/strong> Schedule M requires manufacturers to maintain batch records that allow full traceability of every product from raw materials to finished goods. If a quality issue arises, compliant manufacturers can identify and recall affected batches.<\/li>\n<li><strong>GMP certification is verifiable:<\/strong> Buyers should check that the manufacturer holds a valid GMP certificate issued by the state drug control authority or the CDSCO. The absence of this certificate is a red flag.<\/li>\n<li><strong>Schedule M is not the same as WHO prequalification:<\/strong> While Schedule M alignment with WHO-GMP is a positive step, WHO prequalification is a separate, more rigorous process required for procurement by UN agencies and some international tenders. Buyers sourcing for regulated markets should verify both.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x26a0;&#xfe0f; Challenges in the Transition Period<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The transition to the revised Schedule M has not been smooth for all manufacturers. Several challenges have been reported in the industry press:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Small and medium manufacturers struggling:<\/strong> The Economic Times reported in January 2026 that <strong>only 11% of pharmaceutical units in Himachal Pradesh<\/strong> were fully GMP-compliant under the revised Schedule M, highlighting the scale of the compliance gap among smaller manufacturers.<\/li>\n<li><strong>Extension debates:<\/strong> The government has been discussing whether to grant a one-year extension for small and medium pharma firms to meet the new compliance deadlines, as reported by <strong>KNN India<\/strong> and <strong>Business Standard<\/strong> in December 2025. As of September 2026, the final extension policy was still being finalized \u2014 buyers should check the latest CDSCO guidance.<\/li>\n<li><strong>State-level enforcement:<\/strong> The Telangana Drug Control Administration issued stop-production orders to several companies for non-compliance with the revised Schedule M in early 2026, per <strong>Pharmabiz<\/strong>. This signals that enforcement is becoming more active.<\/li>\n<li><strong>Cough syrup manufacturer audits:<\/strong> In August 2026, over <strong>1,000 cough syrup manufacturers<\/strong> were subjected to intensified audits following quality concerns, as reported by <strong>The New Indian Express<\/strong> \u2014 a clear sign that the regulator is prioritizing high-volume, high-risk product categories.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f50d; Practical Checklist: Verifying Schedule M Compliance<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>If you are buying Indian generic medicines \u2014 whether as a pharmacy, hospital procurement officer, or individual consumer \u2014 use this checklist to verify that the manufacturer takes GMP compliance seriously:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>&#x2705; Request the GMP certificate:<\/strong> Ask the manufacturer or supplier for a copy of their current GMP certificate issued by the state drug control authority. Verify the certificate number with the issuing authority if possible.<\/li>\n<li><strong>&#x2705; Check the CDSCO portal:<\/strong> The CDSCO website (<a href=\"https:\/\/www.cdsco.gov.in\" target=\"_blank\" rel=\"noopener\">cdsco.gov.in<\/a>) provides regulatory information including manufacturer registrations and approval statuses. Cross-check the manufacturer name.<\/li>\n<li><strong>&#x2705; Look for WHO-GMP certification:<\/strong> Manufacturers that have achieved WHO-GMP certification are listed on the WHO Prequalification website. This is a higher benchmark and a strong positive signal.<\/li>\n<li><strong>&#x2705; Verify batch numbers and expiry dates:<\/strong> Every legitimate product should have a clearly printed batch number and expiry date on the packaging \u2014 this is a Schedule M requirement.<\/li>\n<li><strong>&#x26a0;&#xfe0f; Watch for red flags:<\/strong> Missing or unclear labeling, lack of manufacturer address, unusually low prices, and products without batch numbers are all warning signs that the manufacturer may not be compliant.<\/li>\n<li><strong>&#x2705; Use verified distributors:<\/strong> For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a>. Working with verified distributors reduces the risk of sourcing non-compliant products.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">&#x1f52c; The Bigger Picture: India&#8217;s Compliance Trajectory<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>The revised Schedule M is part of a broader pattern of regulatory tightening and modernization by the CDSCO throughout 2025 and 2026. Key developments include:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li><strong>Outsourced GMP audits:<\/strong> The CDSCO&#8217;s plan to outsource GMP inspections to accredited agencies (announced February 2026) is intended to increase inspection capacity and credibility.<\/li>\n<li><strong>1,500-person scientific cadre:<\/strong> Building a larger pool of trained regulatory experts to support inspection and oversight functions, addressing a long-standing capacity constraint.<\/li>\n<li><strong>Digital regulatory platform:<\/strong> The DCGI has announced that the CDSCO will launch the first phase of an end-to-end digital drug regulatory platform within 18 months (as of August 2026), which is expected to streamline approval and compliance tracking workflows.<\/li>\n<li><strong>Risk-based regulation:<\/strong> The September 2026 announcement of a risk-based regulatory framework complements Schedule M by calibrating the intensity of oversight to the risk profile of the manufacturer and product.<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:paragraph -->\n<p>Together, these initiatives signal a regulator that is moving toward greater transparency, capacity, and consistency \u2014 a net positive for buyers who depend on the reliability of Indian-manufactured generic medicines.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Sources: The Economic Times (January 2026) \u2014 &#8220;Schedule M Shock in Himachal: Only 11% Pharma Units Fully GMP-Compliant&#8221;; Pharmabiz (February 2026) \u2014 &#8220;CDSCO To Outsource GMP Audits And Build 1500 Expert Scientific Cadre&#8221;; The New Indian Express (August 2026) \u2014 &#8220;Over 1000 cough syrup manufacturers undergo intense audits&#8221;; IndiaMedToday (February 2026) \u2014 CDSCO regulatory overhaul reporting; KNN India and Business Standard (December 2025) \u2014 Schedule M extension discussions. Details sourced via Google News RSS as of September 14, 2026.<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:post-content -->","protected":false},"excerpt":{"rendered":"<p>&#x26a0;&#xfe0f; Challenges in the Transition Period The transition to the revised Schedule M has not been smooth for all manufacturers. Several challenges have been reported in the industry press: Small and medium manufacturers struggling: The Economic Times reported in January 2026 that only 11% of pharmaceutical units in Himachal Pradesh were fully GMP-compliant under the [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19],"tags":[42,48,29,49],"class_list":["post-3697","post","type-post","status-publish","format-standard","hentry","category-knowledge","tag-cdsco","tag-generic-medicines","tag-india-pharmacy","tag-indian-pharma","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3697"}],"version-history":[{"count":1,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3697\/revisions"}],"predecessor-version":[{"id":3698,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3697\/revisions\/3698"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}